Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Intensive Chemo and RIC Allo-SCT for Refractory/Relapsed Acute Leukemia
NCT01496547Phase 2Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2011
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, cytarabine, idarubicin and busulfan in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Disease-free survival at 2 years. Started Jan 2011; status: completed.
02
Drugs
fludarabinecytarabineidarubicinbusulfan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01496547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496547.